secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001171843-25-007000
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva Q3 2025: revenue $4.48B (+3%), non-GAAP EPS $0.78; Austedo outlook raised; TAPI sale restart
--------------------------------------------------------------------------------

- Revenue $4.48B (+3% YoY); GAAP EPS $0.37, non-GAAP EPS $0.78 (vs $0.69 YoY).
- Austedo revenue $618M (+38% YoY); 2025 outlook raised to $2.05B-$2.15B (from $1.95B-$2.05B).
- Non-GAAP operating margin 28.9% (+86 bps YoY); on track for 30% target by 2027.
- Exclusive TAPI sale discussions terminated; renewed sales process initiated; divestiture intent maintained.
- Full-year 2025 non-GAAP EPS guidance raised to $2.55-$2.65 (midpoint +$0.025); FCF unchanged $1.6B-$1.9B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000117184325007000/0001171843-25-007000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000117184325007000/f8k_110525.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-007000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer